Ftse Mib
34.242,58
0,75%
DAX
18.345,99
0,96%
S&P 500
5.180,74
0,00%
NASDAQ
16.349,25
0,00%
Bitcoin
63.619,07
0,72%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ EyePoint Pharmaceuticals Inc (EYPT) EyePoint Pharmaceuticals Inc (EYPT) Notizie

EYPT

EyePoint Pharmaceuticals (EYPT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EYPT
DataOraFonteTitoloSimboloCompagnia
06/05/202415:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
06/05/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyNASDAQ:EYPTEyePoint Pharmaceuticals Inc
16/04/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
02/04/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina SpecialistsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/03/202419:53Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/03/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/03/202423:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/03/202423:37Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/03/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerNASDAQ:EYPTEyePoint Pharmaceuticals Inc
29/02/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024NASDAQ:EYPTEyePoint Pharmaceuticals Inc
27/02/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
15/02/202403:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
03/02/202422:20GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
02/02/202422:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
31/01/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/01/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular EdemaNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/01/202400:37Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
20/12/202313:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/12/202323:28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/12/202322:01GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/12/202312:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
06/12/202302:18GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingNASDAQ:EYPTEyePoint Pharmaceuticals Inc
05/12/202312:25IH Market NewsMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and MoreNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202322:34Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202322:06GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202313:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary EndpointsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
03/11/202320:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/11/202312:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
31/10/202312:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023NASDAQ:EYPTEyePoint Pharmaceuticals Inc
31/10/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EYPT

La tua Cronologia

BIT
UCG
Unicredit
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
CPR
Davide Campari
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
FBK
Finecobank
BIT
ENI
Eni
BIT
IRE
Iren
BIT
TEN
Tenaris
BIT
LDO
Leonardo
BIT
BPE
Bper Banca
BIT
SRG
Snam
BIT
BAMI
Banco BPM
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network